GHK-Cu: Identity, Evidence, and Documentation

GHK-Cu is cataloged here as a copper(ii) complex of a tripeptide. GHK-Cu is a coordination complex formed by the tripeptide glycyl-L-histidyl-L-lysine and copper(II). Research often examines fibroblast behavior, extracellular-matrix signaling, and copper-dependent effects.

Identity before interpretation

The peptide, the copper ion, and their complex are analytically distinct. A peptide purity result alone does not establish copper loading, complex stoichiometry, quantity, or suitability for a study.

A short catalog name is a starting point, not a complete material characterization. Reproducible work begins by matching the named material to its sequence or chemical form, SKU, lot, nominal quantity, analytical method, and the actual result reported for that sample.

Research questions in the literature

• Fibroblast collagen synthesis and extracellular-matrix remodeling in cell culture.
• Copper-dependent changes in matrix metalloproteinase and inhibitor expression.
• How metal-to-ligand ratio, oxidation state, and analytical method affect material characterization.

These topics describe what investigators measured. They should not be converted into treatment language, consumer promises, or an assumption that a finding transfers across species, tissues, preparations, or experimental conditions.

Evidence map

• A 1988 fibroblast-culture study reported changes in collagen synthesis after exposure to GHK-Cu.
• A 2000 fibroblast-culture study reported changes in MMP-2 and tissue-inhibitor expression and distinguished effects of the complex, copper, and GHK alone.
• These are model-system observations; they do not establish a consumer, cosmetic, or clinical outcome for this catalog material.

Evidence strength depends on the question. A receptor assay can inform target engagement; a cell model can inform a pathway hypothesis; an animal model can inform a defined biological system. None of those alone proves clinical safety, effectiveness, or suitability of a separately sourced material.

Interpretation guardrails

• Cell-culture findings do not establish safety, efficacy, sterility, or performance in a person or animal.
• FDA identifies limited human safety data and immunogenicity and impurity concerns for compounded injectable drugs containing GHK-Cu.
• The Vespera item is a research material, not a cosmetic, medicine, compounded preparation, or approved drug.

Vespera does not translate this literature into dosing, reconstitution, injection, route-of-use, diagnosis, treatment, or veterinary guidance. If a project requires those claims, this catalog and this brief are not the appropriate source.

Lot and COA review

• Review the named chemical form and whether copper content or stoichiometry was measured.
• Match SKU, nominal quantity, lot, method, reported mass, and purity or composition result.
• Separate peptide identity, copper content, microbial controls, and endotoxin data; one result does not substitute for the others.

Chromatographic purity, mass confirmation, quantity, endotoxin, microbial controls, residual solvents, water content, and stability answer different questions. A single headline percentage should not be used as a universal quality score.

Primary and official sources

Read the methods, model, material description, limitations, and conflicts of interest in the source itself.

1. Maquart et al. — GHK-Cu and collagen synthesis in fibroblast culture (1988)In vitro fibroblast study.
2. Siméon et al. — GHK-Cu and MMP-2 expression in fibroblast culture (2000)In vitro extracellular-matrix remodeling study.
3. FDA — bulk substances that may present significant safety risksRegulatory context for compounded injectable drugs containing GHK-Cu.